In EDS ansehen

From routine to selective: how updated MRI guidelines reshape gadolinium use in Germany.

Gespeichert in:

Bibliographische Detailangaben
Titel:	From routine to selective: how updated MRI guidelines reshape gadolinium use in Germany.
Autoren:	Pawlitzki, Marc, Stahmann, Alexander, Frahm, Niklas, Kirstein, Mathia, Peters, Melanie, Flachenecker, Peter, Friede, Tim, Hellwig, Kerstin, Krefting, Dagmar, Mai, Michaela, Warnke, Clemens, Zettl, Uwe K., Ellenberger, David
Quelle:	Neurological Research & Practice; 5/19/2025, Vol. 7 Issue 1, p1-5, 5p
Schlagwörter:	MAGNETIC resonance imaging, GADOLINIUM, TREND analysis, RETROSPECTIVE studies, MULTIPLE sclerosis, PROFESSIONAL standards, CONTRAST media
Geografische Kategorien:	GERMANY
Abstract:	Magnetic resonance imaging (MRI) is a critical diagnostic tool and monitoring modality for multiple sclerosis (MS), frequently employing gadolinium-based contrast agents (Gd). However, concerns regarding the accumulation of Gd have prompted international guidelines (MAGNIMS-CMSC-NAIMS, 2021) to advocate for the limitation of Gd utilization. Consequently, we assessed of the impact of the 2021 guidelines on the use of Gd in MRI in MS patients in Germany by conducting a retrospective analysis of MRI data from 12,833 MS patients in the German MS Register (2019–2024). Generalized additive models were employed to analyze Gd use trends over time by MRI type (cranial, spinal, combined). From 2020 to 2024, a significant decline in Gd use was observed, with percentages dropping from 74.2 to 41.2% in cranial MRI, from 78.2 to 39.2% in spinal MRI and from 81.8 to 59.0% in combined MRI (p < 0.001). The most substantial decline occurred within the initial five years of MS. Gd use in MS MRI scans has significantly decreased in line with the updated guidelines. Nevertheless, its persistent utilization in over one-third of cases necessitates further examination. [ABSTRACT FROM AUTHOR]
	Copyright of Neurological Research & Practice is the property of BioMed Central and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Datenbank:	Complementary Index

Beschreibung
Abstract:	Magnetic resonance imaging (MRI) is a critical diagnostic tool and monitoring modality for multiple sclerosis (MS), frequently employing gadolinium-based contrast agents (Gd). However, concerns regarding the accumulation of Gd have prompted international guidelines (MAGNIMS-CMSC-NAIMS, 2021) to advocate for the limitation of Gd utilization. Consequently, we assessed of the impact of the 2021 guidelines on the use of Gd in MRI in MS patients in Germany by conducting a retrospective analysis of MRI data from 12,833 MS patients in the German MS Register (2019–2024). Generalized additive models were employed to analyze Gd use trends over time by MRI type (cranial, spinal, combined). From 2020 to 2024, a significant decline in Gd use was observed, with percentages dropping from 74.2 to 41.2% in cranial MRI, from 78.2 to 39.2% in spinal MRI and from 81.8 to 59.0% in combined MRI (p < 0.001). The most substantial decline occurred within the initial five years of MS. Gd use in MS MRI scans has significantly decreased in line with the updated guidelines. Nevertheless, its persistent utilization in over one-third of cases necessitates further examination. [ABSTRACT FROM AUTHOR]
DOI:	10.1186/s42466-025-00387-y